Lia Gore, section head of the Center for Cancer and Blood Disorders at Children’s [and professor of pediatrics], said there has been no impact to patients yet and that “we hope that the transfer is seamless for the patients and patient families.” “We are working to understand how quickly new trials can be opened and how to ensure that selected ongoing trials are supported,” Gore said in a statement.
Holly Lindsay, another neuro-oncologist at Children’s [and associate professor of pediatrics], said the hospital is looking for opportunities to continue the care it is already providing to patients under the consortium. “This unpredictability is understandably stressful for families, especially those whose children were enrolled in trials or awaiting new opportunities,” Lindsay said in a statement. “Cancer is the leading cause of medical death in children, and the risk of losing impactful clinical trials is real.”